Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654040 · ClinicalTrials.gov registry record · Phase 1
Liver Transplantation With Tregs at UCSF
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03654040 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 42 participants.
The verdict
NCT03654040, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
Interventions
- DRUG cyclophosphamide
- DRUG everolimus
- PROCEDURE leukapheresis
- DRUG mesna
- BIOLOGICAL arTreg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654040
The ClinicalTrials.gov registry entry for NCT03654040 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT03654040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03654040 about?
NCT03654040 is a clinical study titled "Liver Transplantation With Tregs at UCSF". This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
What is the current status of trial NCT03654040?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-04-22. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT03654040?
The interventions under investigation include: cyclophosphamide (DRUG), everolimus (DRUG), leukapheresis (PROCEDURE), mesna (DRUG), arTreg (BIOLOGICAL).
Who is sponsoring clinical trial NCT03654040?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.